The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 911-918

  Otkjaer, Kristian ^a   Kragballe, K ^a   Funding, A T ^a   Clausen, J T ^b   Noerby, P L ^b   Steiniche, T ^a   Iversen, L ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

IL 19; IL 20; IL 20R ; IL 20R ; IL 22R ; Psoriasis

Indexed keywords

CALCIPOTRIOL; CYCLOSPORIN; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 20 RECEPTOR ALPHA; INTERLEUKIN 20 RECEPTOR BETA; INTERLEUKIN 22 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; MESSENGER RNA; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR DYNAMICS; OBSERVATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PSORIASIS VULGARIS; PUNCH BIOPSY; QUANTITATIVE ASSAY; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CALCITRIOL; CHRONIC DISEASE; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKINS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, INTERLEUKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN;

EID: 27544481752     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06800.x     Document Type: Article

References (18)

1. Parrish-Novak J, Xu W, Brender T et al. Imerleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277:47517-23.
2. Rømer J, Hasselager E, Norby PL et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cydosporine a or calcipotriol. J Invest Dermatol 2003; 121:1306-11.
3. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104:9-19.
4. Fickenscher H, Hor S, Kupers H et al. The interleukin-10 family of cytokines. Trends Immunol 2002; 23:89-96.
5. Gallagher G, Dickensheets H, Eskdale J et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1:442-50.
6. Chang C, Magracheva E, Kozlov S et al. Crystal structure of interleukin-19 defines a new subfamily of helical cytokines. J Biol Chem 2003; 278:3308-13.
7. Dumoutier L, Leemans C, Lejeune D et al. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001; 167:3545-9.
8. Wolk K, Kunz S, Asadullah K et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168:5397-402.
9. Gallagher G, Eskdale J, Jordan W et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004; 4:615-26.
10. Liao YC, Liang WG, Chen FW et al. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002; 169:4288-97.
11. Xu W. Interleukin-20. Int Immunopharmocol 2004; 4:627-33.
12. Ghoreschi K, Thomas P, Breit S et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9:40-6.
13. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002; 13:223-40.
14. Liu L, Ding C, Zeng W et al. Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood 2003; 102:3206-9.
15. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25:169-93.
16. Al-Daraji WI, Grant KR, Ryan K et al. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002; 118:779-88.
17. Vissers WH, Berends M, Muys L et al. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004; 13:106-12.
18. Kragballe K, Iversen L. Calcipotriol. A new topical antipsoriatic. Dermatol Clin 1993; 11:137-41.